We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Fluorimetric Assay Quantifies Galactocerebrosidase Activity in Dried Blood Spots

By LabMedica International staff writers
Posted on 29 Oct 2019
The lysosomal enzyme galactocerebrosidase hydrolyzes glycosidic bonds of several glycosphingolipids, including galactose from galactosylsphingosine (psychosine), and is essential to prevent the toxic accumulation of psychosine in the body.

Decreased galactocerebrosidase (GALC) enzyme activity is causative for Krabbe disease, a lysosomal storage disorder with devastating neurodegenerative consequences. More...
Quantitative fluorimetric assays for GALC activity in isolated blood and skin cells have been described, but not for dried blood spots specimens (DBS).

A team of scientists from the commercial company Baebies, Inc (Durham, NC, USA) and Duke University (Durham, NC, USA) developed a rapid, microtiter plate fluorimetric assay for measuring GALC enzyme activity in DBS specimens using a novel substrate: β-galactose conjugated with a fluorogenic derivative of 6-hexadecanoyl-4-methylumbelliferone with a hydrophobic group.

Samples were obtained as individual punches (3.2 mm diameter) from DBS cards of presumed normal newborns. Archived, deidentified DBS from 10 affected Krabbe disease patients were obtained from the Legacy of Angels Foundation. To extract galactocerebrosidase enzyme from the DBS samples, one punch (3.2 mm) from each DBS was placed in individual wells of a clear, round-bottom, 96-well microtiter plate.

Sample extraction solution (100 μL) was added to each sample well; the plate was covered with a clear adhesive sealer to prevent evaporation and then incubated on a plate-shaker (600 rpm) at room temperature (RT) for 30 minutes. Enzyme activity was determined by adding 10 μL of DBS extract to 10 μL of the GALC substrate solution, which was varied. The fluorescence of the plate, measured as relative fluorescence units (RFU), was read in a Synergy HTX microtiter plate reader with 400 ±15 nm excitation and 485 ±20 nm emission filters.

The GALC assay was carefully optimized to ensure robust performance from the small amount of enzyme present in DBS and to minimize interference from β-galactosidase. The team found that the linear range of the fluorimetric GALC assay encompassed the entire range of samples tested. The activity in the presumed normal samples shows a wide range (0.39 – 15.6 μmol/L/hour) with a population mean of 2.108 μmol/L/hour. As expected, GALC activity in the affected samples is significantly lower than in the presumed normal samples.

The authors concluded that a fluorimetric assay for GALC enzyme activity measurement on dried blood spot specimens is feasible. Improvements to the assay including novel substrate design, increased substrate concentration and removal of sodium chloride maximize the specificity of the assay and minimize interference from β-galactosidase. The study was published on October 16, 2019, in the journal Practical Laboratory Medicine.

Related Links:
Baebies
Duke University


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: HBV RNA in blood is as a stronger predictor of liver cancer risk in patients treated for chronic hepatitis B (Photo courtesy of Adobe Stock)

New Biomarkers Indicate Higher Liver Cancer Risk in Chronic Hepatitis B Patients

Chronic hepatitis B affects around 296 million people worldwide and is a major cause of liver cirrhosis and liver cancer. While modern antiviral treatments can suppress the virus and significantly improve... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.